Abstract
Radiation survival curves for Lewis lung tumours in the lungs ranging in size from 0-5 to 20 mm3 have been obtained, and a size-dependent variation in hypoxic fraction was found. Cell-survival studies following treatment of various sizes of s.c. tumours indicated that the effects of 60Co gamma-rays and the chemotherapeutic agents 1,3-bas(2-chloroethyl)-1-nitrosourea (BCNU) and cyclophosphamide are all size-dependent. Large pulmonary nodules which had regressed but had not been cured by cyclophosphamide regrew with a radiosensitivity that was characteristic of previously untreated tumours. The results give additional experimental support to the clinical interest in early adjuvant therapy of micrometastases, and sequential combined modality therapy for larger tumours.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Stanley, J., Shipley, W. & Steel, G. Influence of tumour size on hypoxic fraction and therapeutic sensitivity of Lewis lung tumour. Br J Cancer 36, 105–113 (1977). https://doi.org/10.1038/bjc.1977.160
Issue Date:
DOI: https://doi.org/10.1038/bjc.1977.160
This article is cited by
-
Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy
Chinese Journal of Cancer (2016)
-
Local failure patterns for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy
Radiation Oncology (2014)
-
Unified approach to growth and aging in biological, technical and biotechnical systems
SpringerPlus (2012)
-
Targeting hypoxic tumour cells to overcome metastasis
BMC Cancer (2011)
-
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy
British Journal of Cancer (2010)